The 2026 Congo Ebola Outbreak: A Rare Strain, a Growing Crisis, and a Glimmer of Hope

The Democratic Republic of the Congo (DRC) is battling its 17th Ebola outbreak, but this one is different. The culprit is the rare Bundibugyo virus, a species for which there is no licensed vaccine and no approved specific treatment. Declared on May 15, 2026, the outbreak has rapidly spread from the epicenter in Ituri province to the neighboring North Kivu and South Kivu provinces, and has crossed the border into Uganda, including its capital, Kampala.

The outbreak’s severity, combined with the unique challenges of the Bundibugyo strain, prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) on May 17, 2026 . As the case count climbs, health authorities are racing to respond with traditional containment measures while the world watches for signs of further spread.

Current Case and Death Toll (as of Early June 2026)

The numbers are a moving target, but the latest official data paints a grim picture of the outbreak's scale.

• Democratic Republic of the Congo: The DRC Ministry of Health reported on June 4 a total of 381 confirmed cases and 64 confirmed deaths, with 233 individuals hospitalized in isolation . Ituri province remains the epicenter, accounting for 359 of the confirmed cases across 17 health zones . In addition, 906 suspected cases and 223 suspected deaths have been recorded, signaling a significant gap in detection and testing .
• Uganda: As of late May, Uganda had confirmed 9 cases and 1 death, all linked to cross-border transmission from the DRC . Uganda also reported four recoveries .
• Combined Figures: A U.S. Centers for Disease Control and Prevention (CDC) report from June 2 tallied a combined 378 confirmed cases and 63 confirmed deaths across both countries .

No cases associated with this outbreak have been reported in the United States .

The Bundibugyo Virus: Why This Outbreak Is Uniquely Dangerous

The Bundibugyo virus was first identified in Uganda in 2007. It is a distinct species from the more common Zaire ebolavirus, which caused the massive 2014–2016 West Africa epidemic. This distinction is critical for one urgent reason: there is no FDA-licensed or authorized vaccine and no approved specific treatment for Bundibugyo virus disease .

The existing Ebola vaccine, ERVEBO®, is only effective against the Zaire species and is not expected to protect against Bundibugyo virus . While the Bundibugyo strain is generally less lethal than Zaire — with a typical fatality rate of 30%–50% compared to 70%–90% — the absence of a pharmaceutical safety net makes containment extremely challenging .

In response, the WHO is accelerating the preparation of clinical trials for experimental treatments and candidate vaccines. Its research advisory group has recommended prioritizing two monoclonal antibodies for evaluation . However, for now, the entire response relies on classic public health pillars.

Geographic Spread and Cross-Border Transmission

The outbreak has not been contained within a single area, complicating control efforts.

• DRC: Three eastern provinces are affected. Ituri is the overwhelming center of the outbreak, hosting 359 of the 381 confirmed cases . Nineteen cases have been reported in North Kivu and three in South Kivu .
• Uganda: The virus has spread from Ituri into Uganda, with confirmed cases appearing in the capital city of Kampala. Uganda closed its border with the DRC on May 27 to curb further spread . The travel of infected individuals before the outbreak was officially declared on May 15 is believed to have seeded this cross-border transmission .

A Critical Gap: Insufficient Contact Tracing

With no medical countermeasures, contact tracing is the single most powerful tool to break chains of transmission. However, current efforts are falling short.

As of early June, over 500 contacts were being monitored in the DRC and over 100 in Uganda, but the proportion of listed contacts actually reached and tracked remains insufficient for effective containment . Another tracker reported that contact tracing in Ituri was at just 39.3%, far below the >90% coverage needed to stay ahead of the virus . The massive number of suspected cases—906 compared to 381 confirmed—is a red flag indicating extensive undetected transmission in the community .

The outbreak is also unfolding in a context of armed conflict, population displacement, and fragile health infrastructure in eastern DRC, all of which impede safe and timely contact tracing .

International Response: US Entry Restrictions and Travel Advisories

The United States moved swiftly to prevent the importation of cases.

• Entry Ban: On May 18, 2026, the CDC issued a public health order suspending entry into the U.S. for foreign nationals who had been physically present in the DRC, Uganda, or South Sudan within the prior 21 days .
• Enhanced Screening: US citizens and lawful permanent residents are permitted to enter but must arrive through designated airports and undergo enhanced public health screening and 21 days of symptom monitoring .
• Travel Advisory: The U.S. State Department issued a Level 4: “Do Not Travel” advisory for the DRC, citing the Ebola outbreak alongside existing dangers of crime, unrest, and terrorism .

Other countries and agencies have taken similar steps. The European Centre for Disease Prevention and Control (ECDC) has advised EU/EEA countries to review and update their isolation and contact-tracing procedures .

A Rare Bright Spot: Recovered Healthcare Workers

Amid the grim numbers, there is a sign that survival is possible even without a specific antiviral. On May 31, WHO Director-General Tedros Adhanom Ghebreyesus announced during a visit to Bunia, the capital of Ituri, that four nurses who had contracted Ebola had fully recovered and been discharged from the hospital . A laboratory worker had already been discharged days earlier, bringing the total number of recoveries in the DRC to five .

This demonstrates that with early diagnosis and proactive supportive care—including fluid and electrolyte management and treatment of complications—patients can survive, even with no targeted drug to fight the virus . The WHO has since reported eight total patients discharged, including two from Uganda . This outcome, however, has been offset by the toll on healthcare workers: the Africa CDC reports that 34 health workers have been infected in this outbreak, with 7 fatalities .

What to Watch For

The crisis is highly dynamic. Key indicators to follow include whether contact tracing rates improve toward the 90% threshold, the speed at which experimental vaccines enter clinical trials, and any further geographic spread both inside and outside the current affected countries. The WHO has requested $115 million over three months for the response, and as of early June, only 35% of that goal had been met, raising serious concerns about the sustainability of the international effort .